Sunshine tour prohibited list 2013
SUNSHINE TOUR ANTI-DOPING PROGRAM
PROHIBITED LIST 2013
SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES
Peptide Hormones, Growth Factors and Related Substances
The use of any drug should be limited to medically justified indications
Any pharmacological substance which is not addressed by any of the subsequent sections of the
List and with no current approval by any governmental regulatory health authority for human
therapeutic use (i.e. drugs under pre-clinical or clinical development or discontinued, designer
drugs, veterinary medicines) is prohibited at all times. S1.
Anabolic Agents are prohibited. 1.
Anabolic Androgenic Steroids (AAS)
a. Exogenous1 AAS, including:
(5α-androst-1-ene-3β,17β-diol ); 1-androstenedione
(estr-4-ene-3β,17β-diol ); bolasterone; boldenone; boldione
methyl-5α-androst-2-en-17β-ol); drostanolone; ethylestrenol
fluoxymesterone; formebolone; furazabol
androstan-17β-ol); gestrinone; 4-hydroxytestosterone
one); mestanolone; mesterolone; metenolone; methandienone
mibolerone; nandrolone; 19-norandrostenedione
androstane); quinbolone; stanozolol; stenbolone; 1-testosterone
and other substances
with a similar chemical structure or similar biological effect(s).
b. Endogenous2 AAS when administered exogenously: androstenediol
(dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one); testosterone;
and their metabolites and isomers, including but not limited to:
1 Exogenous refers to a substance which is not ordinarily capable of being produced by the body naturally. 2 Endogenous refers to a substance which is capable of being produced by the body naturally
5α-androstane-3α,17α-diol; 5α-androstane-3α,17β-diol; 5α-androstane-3β,17α-diol; 5α-
androstane-3β,17β-diol; androst-4-ene-3α,17α-diol; androst-4-ene-3α,17β-diol; androst-
4-ene-3β,17α-diol; androst-5-ene-3α,17α-diol; androst-5-ene-3α,17β-diol; androst-5-
(androst-5-ene-3,17-dione); epi-dihydrotestosterone; epitestosterone; etiocholanolone;
3α-hydroxy-5α-androstan-17-one; 3β-hydroxy-5α-androstan-17-one; 7α-hydroxy-DHEA
; 7β-hydroxy-DHEA ; 7-keto-DHEA; 19-norandrosterone; 19-noretiocholanolone.
Other Anabolic Agents, including but not limited to:
Clenbuterol, selective androgen receptor modulators (SARMs), tibolone, zeranol,
PEPTIDE HORMONES, GROWTH FACTORS AND RELATED SUBSTANCES
The following substances and their releasing factors are prohibited: 1. Erythropoiesis-Stimulating Agents [
e.g. erythropoietin (EPO), darbepoietin (dEPO),
hypoxia-inducible factor (HIF) stabilizers, methoxy polyethylene glycol-epoetin beta
(CERA), peginesatide (Hematide];
2. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH)
4. Growth Hormone (GH), Insulin-like Growth Factor-1
(IGF-1), Fibroblast Growth Factors
(FGFs); Hepatocyte Growth Factor (HGF); Mechano Growth Factors (MGFs); Platelet-
Derived Growth Factor (PDGF); Vascular Endothelial Growth Factor (VEGF)
as well as
any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation,
vascularisation, energy utilization, regenerative capacity or fibre type switching;
and other substances with similar chemical structure or similar biological effects(s).
S3. HORMONE AND METABOLIC MODULATORS
The following classes are prohibited: 1.
including, but not limited to, aminoglutethimide, anastrozole,
androsta-1,4,6-triene-3,17-dione (androstatrienedione), 4-androstene-3,6,17 trione
(6-oxo) exemestane, formestane, letrozole, testolactone.
Selective Estrogen Receptor Modulators (SERMs)
including, but not limited to, raloxifene, tamoxifen, toremifene
Other anti-estrogenic substances
including, but not limited to, clomiphene, cyclofenil,
Agents modifying myostatin function(s
) including, but not limited to, myostatin
Metabolic modulators: Insulins and Peroxisome Proliferator Activated Receptor δ
(PPARδ) agonists (e.g. GW 1516), PPARδ-AMP-activated protein kinase (AMPK)
axis agonists (e.g.AICAR)
S4. DIURETICS AND OTHER MASKING AGENTS
Masking agents are prohibited. They include: Diuretics3, desmopressin, plasma expanders (
; intravenous administration of albumin, dextran, hydroxyethyl starch
and mannitol), probenecid,
and other substances with
similar biological effect(s). Local application of felypressin in dental anaesthesia is not prohibited.
Diuretics include: Acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid,
furosemide, indapamide, metolazone, spironolactone, thiazides
chlorothiazide, hydrochlorothiazide), triamterene,
and other substances with a similar
chemical structure or similar biological effect(s) (except drosperinone, pamabrom and topical
dorzolamine and brinzolamide, which are not prohibited).
The use of any quantity of a substance subject to the threshold limits (i.e. formoterol, salbutamol,
cathine, ephedrine, methylephedrine and pseudoephedrine) in conjunction with a diuretic or other
masking agent requires the deliverance of a specific Therapeutic Use Exemption for that
substance in addition to the one granted for the diuretic or other masking agent.
S5. BETA BLOCKERS
The entire class of Beta Blockers
is prohibited, including but not limited to the following: Acebutolol, alprenolol, atenolol, bendroflumethiazide, betaxolol, bisoprolol, bunolol,
carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol,
nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol.
All stimulants (including both optical isomers where relevant) are prohibited, except imidazole
derivatives for topical use and those stimulants included on the 2013 SUNSHINE TOUR
a: Non-Specified Stimulants: Adrafinil; amfepramone; amiphenazole; amphetamine; amphetaminil; benfluorex;
benzphetamine; benzylpiperazine; bromantan; clobenzorex; cocaine; cropropamide;
crotetamide; dimethylamphetamine; etilamphetamine; famprofazone; fencamine;
fenetylline; fenfluramine; fenproporex; furfenorex; mefenorex; mephentermine; mesocarb;
methamphetamine(d-); p-methylamphetamine; methylenedioxyamphetamine;
methylenedioxymethamphetamine; modafinil; norfenfluramine; phendimetrazine;
phenmetrazine; phentermine; 4-phenylpiracetam (carphedon); prenylamine; prolintane.
A stimulant not expressly listed in this section is a Specified Substance.
4 The following substances included on the 2013 SUNSHINE TOUR Monitoring List: (bupropion, caffeine, nicotine,
phenylephrine, phenylpropanolamine, pipradol, synephrine) are not
considered Prohibited Substances.
b: Specified Stimulants (examples): Adrenaline**; cathine***; ephedrine****; etamivan; etilefrine; fenbutrazate; fencamfamin;
heptaminol; isometheptene; levmetamfetamine; meclofenoxate; methylephedrine****;
methylhexaneamine (dimethylpentylamine); methylphenidate; nikethamide; norfenefrine;
pentetrazol; phenpromethamine; propylhexedrine; pseudoephedrine*****; selegiline;
sibutramine; strychnine; tuaminoheptane;
and other substances with a similar chemical
structure or similar biological effect(s).
** Local administration (e.g. nasal, ophthalmologic) of Adrenaline
or co-administration with local
anaesthetic agents is not prohibited.
is prohibited when its concentration in urine is greater than 5 micrograms per milliliter.
**** Each of ephedrine
is prohibited when its concentration in urine is
greater than 10 micrograms per milliliter.
is prohibited when its concentration in urine is greater than 150
micrograms per milliliter. S7. NARCOTICS
The following narcotics are prohibited: Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives,
The presence of hydrocodone, morphine/codeine ratio; tramadol will be monitored
in order to
detect patterns of misuse in golf.
Natural (e.g. cannabis, hashish, marijuana) or synthetic delta 9-tetrahydrocannabinol (THC) and
cannabimimetics (e.g.”Spice”, JWH018, JWH073, HU-210) are prohibited. S9. GLUCOCORTICOSTEROIDS
All glucocorticosteroids are prohibited when administered by oral, intravenous, intramuscular or
rectal routes. Their use requires a Therapeutic Use Exemption Application and approval.
iontophoresis/phonophoresis), gingival, nasal, ophthalmic and perianal disorders are not
Intraarticular, periarticular, peritendinous, epidural, intradermal injections and inhalation routes
are not prohibited. S10. BETA-2 AGONISTS
All beta-2 agonists (including both optical isomers where relevant) are prohibited except inhaled
salbutamol (maximum 1600 micrograms over 24 hours), inhaled formoterol (maximum 54
micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with
manufacturers’ recommended therapeutic regime.
The presence of salbutamol in urine in excess of 1000ng/ml or formoterol in excess of 40ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding unless the Player proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of a therapeutic dose up to the maximum indicated above. Terbutaline when administered by inhalation, requires a Therapeutic Use Exemption application. A TUE application should be submitted and a Medical File prepared and submitted on request when a TUE is required, for example to explain an Adverse Analytical Finding.
MANIPULATION OF BLOOD AND BLOOD COMPONENTS
The following are prohibited:
The administration or reintroduction of any quantity of autologous, homologous or heterologous blood or red blood cell products of any origin into the circulatory system.
Artificially enhancing the uptake, transport or delivery of oxygen, including but not limited to perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products, excluding supplemental oxygen.
Any form of intravascular manipulation of the blood or blood components by physical or chemical means.
CHEMICAL AND PHYSICAL MANIPULATION
The following are prohibited:
, in order to alter the integrity and validity of Samples
collected during Doping Control
is prohibited. These include but are not limited to urine substitution and/or adulteration (e.g. proteases).
Intravenous infusions and/or injections of more than 50 mL per 6 hour period are prohibited except for those legitimately received in the course of hospital admissions or clinical investigations.
M3. GENE DOPING
The following, with the potential to enhance sport performance, are prohibited:
The transfer of polymers of nucleic acids or nucleic acid analogues;
The use of normal or genetically modified cells;
Estado de Santa Catarina PREFEITURA MUNICIPAL DE ÁGUAS MORNAS CNPJ: 82.892.266/0001-50 SECRETARIA DE ADMINISTRAÇÃO E FINANÇAS COMISSÃO PERMANENTE DE LICITAÇÃO PROCESSO N.º 18/2012 MODALIDADE: PREGÃO PRESENCIAL – SISTEMA DE REGISTRO DE PREÇOS TIPO DE LICITAÇÃO : MENOR PREÇO POR ITEM SESSÃO PÚBLICA PARA RECEBIMENTO DOCUMENTAÇÕES E RECEBIMENTO E ABERTURA DAS PROPO
Nils Kaland, dr. polit, forskningmessig tilknyttet Høgskolen i Lil ehammer,arbeider deltid ved Lil ehammer voksenopplæringssenter Bakgrunn en påfallende sosial atferd, og Wing (1996) lanserte Autisme ble første gang beskrevet i 1940-årene (kan-begrepet autism spectrum disorders3 – autismespek-ner, 1943), men det er først i løpet av de siste årene at terforstyrrelser – for å ret